Skip to Main Content
Alzheimer's Disease | Mental Health & Behavioral Research

Ketamine for the Treatment of Depression in Parkinson's Disease

What is the purpose of this trial?

The main purpose of this study is to examine the efficacy, safety and mechanistic underpinnings of a repeated dosing ketamine infusion paradigm compared to placebo in individuals with PD.

A subset of participants in each arm will undergo baseline and post-treatment PET and fMRI scans, to examine whether changes in synaptic density and reorganization of functional networks underlie ketamine's putative antidepressant effects in PD.

  • Trial with
    Michael J. Fox Foundation
  • Ages
    40 years - 70 years
  • Gender
    Both

Contact Information

For more information about this study, including how to volunteer, contact Sophie E Holmes

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    04/24/2024
  • Study HIC
    #2000030394